Status:
RECRUITING
Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy - Observational Long-term Outcome Follow up
Lead Sponsor:
Artcline GmbH
Collaborating Sponsors:
ZKS Jena
Conditions:
Severe Sepsis
Eligibility:
All Genders
18-80 years
Brief Summary
Subjects previously enrolled / randomized in the ReActIF-ICE (Recovery from acute immune failure in septic shock by immune cell extracorporeal terapy - immune competence enhancement) study received ei...
Detailed Description
Sepsis is a worldwide health threat because of high mortality and the development of long-lasting disabilities, including physical and cognitive impairment and mental disorders, known collectively as ...
Eligibility Criteria
Inclusion
- Subject or legal surrogate is willing and able to provide written informed consent and comply with all protocol requirements or the implementation of other established procedures according to the local regulations of the contributing center to include subjects who are unable to provide informed consent.
- Subject was enrolled in the ReActIF-ICE study and successfully passed the Day 2 re-evaluation of that trial.
Exclusion
- none
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2030
Estimated Enrollment :
142 Patients enrolled
Trial Details
Trial ID
NCT06143137
Start Date
January 1 2024
End Date
February 28 2030
Last Update
August 2 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Klinikum Magdeburg, Klinik für Intensiv- und Rettungsmedizin
Magdeburg, Germany, 39130
2
Universitätsmedizin Rostock, Abteilung KAI
Rostock, Germany